8-K/A: N2OFF Acquires MitoCareX Bio, Targets NSCLC Drug Resistance

N2OFF, Inc. has acquired MitoCareX Bio, a drug discovery company focused on developing cancer therapeutics for Non-Small Cell Lung Cancer by targeting mitochondrial carrier proteins.

Summary

• N2OFF, Inc. completed the acquisition of MitoCareX Bio Ltd. on October 20, 2025, making MitoCareX a wholly-owned subsidiary.
• MitoCareX Bio is a drug discovery company focused on developing anti-cancer small molecule therapeutics (ACSMT) by targeting the mitochondrial carrier family (SLC25A proteins), with an initial focus on Non-Small Cell Lung Cancer (NSCLC).
• The company's core technology includes MITOLINE, a proprietary algorithm for generating reliable 3D molecular models of SLC25A proteins, an advanced cloud-based computational chemistry platform, and novel in-vitro screening platforms.
• MitoCareX has identified 'hit compound 1' as an active anti-cancer molecule in in-vitro screenings and is developing derivatives to overcome drug resistance in EGFR therapies and platinum-based chemotherapies for lung adenocarcinoma.
• Bioinformatic analysis of TCGA data showed upregulated expression of MitoCareX's target protein is associated with worse patient survival in lung adenocarcinoma, especially with mutated EGFR.
• In-vitro studies using 3D NSCLC spheroid systems demonstrated that knocking down the target protein significantly reduced spheroid size and viability in NCI-H1299 and NCI-H1975 cell lines.
• MitoCareX has incurred significant operating losses since inception, with a net loss of $581,000 for the six months ended June 30, 2025, and an accumulated deficit of $2,341,000.
• The company's provisional patent applications for 'hit compound 1' in the USA were withdrawn in February 2025 as scientific results did not support prosecution.
• N2OFF's total consideration for the acquisition was approximately $8.863 million, comprising $700,000 cash, $4.839 million in N2OFF common stock, $2.034 million in contingent share consideration, and $1.290 million in contingent cash consideration.
• N2OFF has committed an initial investment of $1 million to MitoCareX, net of prior loans totaling $1.122 million.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative due to significant accumulated losses, ongoing cash burn, early stage of development, and the withdrawal of patent applications for its lead compound. While the acquisition by N2OFF provides capital and the technology has potential, the inherent risks of drug discovery, especially at such an early stage, and the recent IP setback weigh heavily.

Positives

• MitoCareX possesses proprietary technology, MITOLINE, which addresses a major challenge in SLC25A related drug discovery by generating reliable 3D protein models.
• The company has developed advanced computational and in-vitro screening platforms, including 3D NSCLC tumor spheroid systems, to accelerate drug discovery and validation.
• Initial in-vitro validation of 'hit compound 1' demonstrated anti-cancerous activity and potential to overcome drug resistance in NSCLC, a significant unmet medical need.
• Bioinformatic analysis supports the target protein's relevance, showing its upregulation correlates with worse survival in lung adenocarcinoma, particularly with mutated EGFR.
• The global markets for mitochondria-based therapies, 3D protein structure analysis, and lung adenocarcinoma treatment are projected for significant growth (CAGRs of ~7.7%, ~10%, and 10.7% respectively).
• The acquisition by N2OFF provides MitoCareX with substantial funding and integration into a publicly traded company, potentially enhancing its development capabilities and market visibility.
• The management team includes experienced scientists and biotech leaders with strong interdisciplinary backgrounds and proven track records.

Negatives

• MitoCareX has no operating history, no products approved for commercial sale, and has not generated any revenue since its inception in February 2022.
• The company has incurred recurring losses from operations, with an accumulated deficit of $2,341,000 as of June 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• Provisional patent applications for 'hit compound 1' were withdrawn in February 2025 because scientific results did not support prosecution, indicating a setback in intellectual property protection for its lead candidate.
• All of MitoCareX's ACSMT programs are still in the preclinical or discovery stage, requiring substantial additional development time and resources before regulatory approval and commercialization.
• The company will require substantial additional capital to finance its operations, and there are no assurances that adequate financing will be obtained on acceptable terms.
• The acquisition by N2OFF involves significant dilution for existing N2OFF shareholders, with up to 40% of fully diluted common stock issued at closing, plus potential additional shares and contingent cash payments.

Risks

• The market price of N2OFF's Common Stock may decline due to the acquisition, including dilution from the issuance of shares (40% initial, up to 25% additional contingent, 5% RSU for CEO) and contingent cash payments.
• The integration of MitoCareX may result in significant accounting charges and unexpected consequences, as not all risks may have been discovered during due diligence.
• MitoCareX may experience difficulties in recruiting additional qualified employees and consultants, which could disrupt operations and divert management's attention.
• MitoCareX has no operating history, no approved products, and its scientific approach is unproven, making predictions about future success uncertain.
• The company has incurred significant operating losses since inception and expects to continue incurring substantial losses for the foreseeable future, potentially impairing its ability to raise capital or continue operations.
• Failure to obtain substantial additional capital when needed could force delays, reductions, or termination of ACSMT development programs, MITOLINE validations, or commercialization efforts.
• Conducting preclinical studies and clinical trials is time-consuming, expensive, and uncertain, and MitoCareX may never generate the necessary data for regulatory approval and commercialization.
• Raising additional capital through collaborations or licenses may require relinquishing valuable rights to future revenue streams, ACSMT, or intellectual property.
• Intellectual property protection is uncertain; patents may be challenged, narrowed, circumvented, or invalidated, and competitors may independently develop similar technologies.
• The extensive time required for development, testing, and regulatory review means any related patents may expire or remain in force for only a short period post-commercialization.
• Reliance on trade secret protection carries risks of independent development by third parties or breaches of confidentiality agreements.
• MitoCareX does not own or operate manufacturing facilities and relies on third parties, introducing potential supply chain and quality control risks.
• The company currently has no sales, marketing, or commercial product distribution capabilities and intends to build this infrastructure over time, which is a significant undertaking.

Future Outlook

MitoCareX expects to continue incurring net losses and negative cash flows for the foreseeable future as it progresses its preclinical studies and clinical trials. The company aims to clinically test its final lead product initially for previously treated advanced NSCLC patients, focusing on overcoming drug resistance to EGFR inhibitors and platinum-based chemotherapies. Future plans include optimizing MITOLINE, ongoing in-silico and in-vitro screenings for new chemical scaffolds, synthesizing derivatives of 'hit compound 1', and evaluating combination therapies. Commercialization efforts may involve partnerships, licensing MITOLINE, and potentially building its own sales and marketing infrastructure in the US and other regions.

Management Comments

• MitoCareX's mission is to be the foremost biopharma company that develops and delivers transformative metabolic-based therapies that improve and extend the lives of patients.
• Current published inhibitors targeting MitoCareX's target protein fail to demonstrate necessary drug-like properties and hence could not be progressed towards clinical trials.
• MitoCareX considers itself a unique company that addresses a major problem and market gap in overcoming drug resistance in NSCLC.
• The company believes its approach, development and commercial strategy, scientific capabilities, know-how, and experience provide competitive advantages.

Industry Context

MitoCareX operates in the highly competitive and rapidly evolving biopharmaceutical industry, specifically within oncology and computational drug discovery. Its focus on mitochondrial carriers (SLC25A family) represents a novel approach to cancer therapy, as no FDA-approved drugs currently target this protein family directly. The company leverages growing trends in 3D protein structure analysis and AI-based drug prediction tools. Its strategy to address drug resistance in NSCLC, particularly for EGFR-mutated and chemotherapy-resistant lung adenocarcinoma, aligns with a significant unmet medical need in a large and growing market. The synthetic lethality approach is a recognized strategy in precision oncology, with PARP inhibitors being a successful example, suggesting a valid scientific premise for MitoCareX's research.

Comparison to Industry Standards

• MitoCareX's use of 3D spheroid systems for NSCLC cells better mimics the in vivo tumor structure and microenvironment compared to traditional 2D cultures, which is a recognized advancement in cancer metabolism research (PMID 28615311, PMID 24797513, PMID 27663511).
• The company's approach to targeting EGFR inhibitor resistance in NSCLC aligns with industry efforts to overcome a major challenge, as resistance to third-generation TKIs like Osimertinib is inevitable (PMID 36482474).
• MitoCareX's strategy of developing combination therapies, particularly with EGFR TKIs or platinum-based medicines, is a common and often necessary approach in oncology to improve survival outcomes and overcome resistance, as highlighted by the need for combinational therapy in lung cancer (PMID 37240224).
• The company faces competition from established players like Relay Therapeutics (Dynamo platform, integrating dynamic protein motion with AI), Daiichi Sankyo (Patritumab deruxtecan, an HER3 ADC with priority review), and Scorpion Therapeutics (STX-241, a 4th-gen EGFR inhibitor addressing resistance), indicating a competitive landscape for novel drug discovery and NSCLC treatments.
• The withdrawal of provisional patent applications for 'hit compound 1' due to insufficient scientific support is a setback, contrasting with the robust IP portfolios typically built by successful biopharma companies and potentially impacting its competitive positioning.

Management Changes

Related Party Transactions

• N2OFF, Inc. (the acquirer) provided multiple short-term loans to MitoCareX Bio Ltd. totaling $1,122,000.
• L.I.A Pure Capital Ltd., a related party, provided guarantees to N2OFF for these short-term loans.
• SciSparc Ltd., an investor in MitoCareX, was a seller in the acquisition and received cash and N2OFF shares.

Stakeholder Impact

• **Shareholders (N2OFF):** Significant dilution from the issuance of common stock (40% initially, up to 25% contingent) and potential future cash payments (30% of financing proceeds capped at $1.6M) to MitoCareX sellers. Potential for share price decline due to these factors and integration costs.
• **Shareholders (MitoCareX Sellers):** Received cash and N2OFF common stock, with potential for additional contingent shares and cash based on milestones and future financing, providing a monetization event for their investment.
• **Employees (MitoCareX):** Dr. Alon Silberman (Co-Founder, CSO) will serve as CEO of MitoCareX post-acquisition, receiving restricted stock units, indicating continuity in leadership. Potential for expansion of the organization and recruitment of additional personnel.
• **Patients (NSCLC):** Potential for new therapeutic options to overcome drug resistance in NSCLC, addressing a significant unmet medical need, if MitoCareX's drug candidates successfully progress through development and regulatory approval.
• **Creditors (N2OFF):** N2OFF has provided substantial loans to MitoCareX, which are now part of the combined entity's financial structure.

Next Steps

• Optimize MITOLINE using ensemble docking and/or molecular dynamics-based methods.
• Perform ongoing in-silico and in-vitro screenings to recognize additional chemical scaffolds as potential anti-cancer therapeutics.
• Synthesize derivatives related to 'hit compound 1' and conduct Structure Activity Relationship (SAR) studies.
• Evaluate in-vitro the influence of 'hit compound 1' with or without FDA-approved tyrosine kinase inhibitors or platinum-based medicines.
• Test developed compounds in a dedicated preclinical setting following in-vitro evaluations.
• Progress 'hit-to-lead' medicinal chemistry campaign aimed at optimizing the structure of 'hit compound 1'.
• Potentially pursue partnerships for early revenue and co-development or out-licensing at later stages.
• Commercialize MITOLINE through licensing and strategic partnerships, including upfront fees, milestone payments, and royalties.
• N2OFF to provide an initial investment of $1,000,000 to MitoCareX (net of prior loans).

Key Dates

Recommendation

The acquisition of MitoCareX Bio by N2OFF, Inc. presents a high-risk, high-reward scenario. While MitoCareX possesses innovative technology (MITOLINE) and targets a significant unmet medical need in NSCLC drug resistance, it is an early-stage drug discovery company with no revenue, substantial accumulated losses, and a going concern warning. The recent withdrawal of patent applications for its lead compound is a notable setback. The acquisition provides necessary capital and a public platform, but also introduces significant dilution for N2OFF shareholders and substantial integration risks. Given the very early stage of drug development, the long and uncertain path to commercialization, and the recent IP challenge, a 'hold' recommendation is appropriate. Investors should monitor preclinical and clinical trial progress, future capital raises, and intellectual property developments closely before considering further investment. The potential for transformative therapies is present, but so are considerable execution and financial risks.

Keywords

MitoCareX Bio, N2OFF Inc, NSCLC, Non-Small Cell Lung Cancer, Cancer Therapeutics, Mitochondrial Carrier Proteins, SLC25A, Drug Discovery, Computational Chemistry, Structural Biology, MITOLINE, EGFR Inhibitor Resistance, Chemotherapy Resistance, Synthetic Lethality, Biopharmaceutical, Preclinical Development, Oncology, Biotech Acquisition